Overview of Synolis V-A

Property	Description
Active Ingredient	Sodium Hyaluronate (Hyaluronic Acid salt)
Form	Sterile, Viscoelastic Injectable Solution (Gel)
Pharmacological Class	Viscosupplementation Agent (Medical Device)
Common Therapeutic Use	Management of pain and mobility issues in mild to moderate Osteoarthritis (OA)
Origin / Manufacturer	Non-animal source (Bio-fermentation) / Aptissen SA, Switzerland

Synolis V-A is a specialized, viscoelastic injectable solution classified as a medical device for viscosupplementation, a therapy used to temporarily restore the lubricating and shock-absorbing properties of joint fluid. This product is administered by a healthcare professional directly into the affected joint, such as the knee or hip, as a treatment option for symptomatic mild to moderate osteoarthritis (OA).

Key Ingredients: Composition and Differentiation

The core components of Synolis V-A are high-molecular-weight Sodium Hyaluronate (HA) and Sorbitol, an antioxidant agent. The Sodium Hyaluronate used is produced through bio-fermentation, ensuring it is of non-animal origin. The inclusion of Sorbitol is a distinguishing feature, as it is designed to stabilize the HA component, protecting it from premature degradation within the joint space. This combination is formulated to exhibit specific rheological properties—viscosity and elasticity—that closely mimic those of healthy, young synovial fluid.

Therapeutic Purpose and Action Principle

Synolis V-A is indicated for the reduction of pain and the improvement of joint mobility in synovial joints affected by degenerative changes, such as those caused by OA. The therapy is clinically recognized for addressing the core biomechanical problem of degraded joint fluid in OA. By physically restoring the fluid's quality, it enhances joint lubrication and provides a cushion against impact. This physical enhancement allows patients to regain a greater range of comfortable motion.

Regulatory References

Viscosupplementation for Osteoarthritis

What side effects are possible with Synolis V-A?

Possible side effects and safety information

Regulatory documents classify the adverse reactions associated with this viscoelastic solution primarily into localized effects and rare systemic events. The safety profile is structured to address consequences related to the injection procedure and the product's components (Sodium Hyaluronate and Sorbitol).

Adverse Reaction Scope

Classification	Examples of Officially Documented Events
Common, Localized	Injection-site pain, swelling (oedema), warmth, redness (erythema), and joint effusion (fluid accumulation). These effects are generally transient and resolve spontaneously within a few days.
Rare, Serious	Systemic events like anaphylactic reactions (severe allergic response) and severe localized reactions such as pseudo-septic arthritis (acute inflammation mimicking infection) have been reported rarely.

Safety Constraints and Restrictions

Official labeling defines specific safety constraints for administration. The product is contraindicated in patients with a known hypersensitivity to either Sodium Hyaluronate or Sorbitol. Furthermore, it must not be administered into a joint that is infected or acutely inflamed, nor in areas with skin diseases or infections near the intended injection site.

A key procedural safety note is the incompatibility with disinfectants containing quaternary ammonium salts, which can cause the product to precipitate. Administration is not recommended in pregnant or breast-feeding women or in pediatric patients due to limited clinical data.

Overdose and Emergency Response

Overdose and When to Seek Help

Synolis V-A is an intra-articular injectable medical device, not a systematically absorbed drug subject to the traditional definition of drug overdose involving systemic toxicity or organ failure. Consequently, authoritative government regulatory documents for this product and its class do not describe a systemic overdose syndrome.

Official Regulatory Context

Overdose Concept	Regulatory Information
Systemic Overdose	Not applicable. No systemic toxicity profile is defined for this product type.
Dose-Related Risk	The product is designated for single-use only; reuse is explicitly stated to void sterility.
Primary Risk of Misuse	Reuse of the single-use product may cause infections, as sterility is compromised.

Procedural Safety Statements

Official documents define safety around proper administration and local adverse events rather than chemical toxicity. The primary requirement for seeking follow-up medical attention relates to local reactions at the injection site.

Required Follow-Up: Patients are instructed to inform their physician if local side effects, such as pain, swelling (oedema), or joint fluid accumulation (effusion), persist for over a week following the injection.
Action for Any Side Effect: The patient should also inform the doctor if any other side effects occur.

Immediate medical attention is required in accordance with local emergency protocols for injection-related complications, severe adverse reactions, or signs of infection.

The regulatory profile emphasizes that risks are procedural and related to product misuse, specifically the risk of infection from reusing the single-use container, rather than a toxic reaction from excessive chemical dosage.

Therapeutic Uses of Synolis V-A

What Synolis V-A Treats: Main Uses and Benefits

Synolis V-A is commonly used across domains where additional symptomatic support is needed in the management of symptomatic mild to moderate osteoarthritis (OA) of the knee and hip. This therapy is applied in addressing the chronic joint pain and discomfort associated with this degenerative disease.

This supportive application is primarily relevant for easing symptoms related to physical discomfort, functional stiffness, and restricted joint mobility. It is generally considered relevant in clinical situations where pain and restricted movement actively interfere with routine activities, contributing to improved comfort during periods of heightened symptoms and helping patients cope more steadily with symptom fluctuations.

Quick Fact: Support for Joint Discomfort

The therapy is applied in addressing symptom clusters that may become disruptive, such as persistent pain on motion and difficulty moving the joint smoothly, particularly when symptoms related to physical discomfort persist. This focus on functional support assists with managing the noticeable interference of OA symptoms with daily functioning.

“This application helps address symptom clusters that may become disruptive, supporting patients during episodes of heightened discomfort.”

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

Regulatory documents define specific populations and conditions where the use of Synolis V-A is either strictly prohibited (contraindicated) or requires restricted/conditional use by a physician.

Classification	Who Must Not Use (Contraindicated)
Allergy	Patients with known hypersensitivity or allergy to sodium hyaluronate and/or sorbitol preparation.
Age Restriction	Young people under the age of 18 years.
Reproductive Status	Pregnant women and breastfeeding women.
Local Condition	Patients with a skin disorder or an infection at the site of the injection or an infected or seriously inflamed joint.

Conditions Requiring Restricted or Conditional Use

Use of Synolis V-A in certain patient categories is not absolutely prohibited, but requires a careful, case-by-case decision by the administering physician due to a lack of established clinical data on tolerance and efficacy. The product information recommends careful monitoring for these groups:

Patients with antecedent or active auto-immune disease.
Patients with an abnormal physiological condition.
A joint presenting with important venal or lymphatic stasis in the limb.
A joint with significant effusion, which must be aspirated before injection.

What should I know about interactions with other medicines?

Interaction Scope

Property	Description
Medicinal product categories with documented interactions:	Disinfectants containing quaternary ammonium salts. Other intra-articular injectables (compatibility not established).
Specific interacting medicines (if explicitly listed):	Benzalkonium Chloride.
Mechanistic basis of interactions:	Localized physical incompatibility (leading to precipitation).
Interaction-related restrictions:	The product must never come into contact with quaternary ammonium salts or medical/surgical equipment treated with these substances.

Interaction Classifications (High-Level)

Classification	Description
Interaction severity classification:	Contact is prohibited due to the risk of physical precipitation and subsequent localized inactivation of the product.
Interaction-context constraints:	The contact avoidance rule applies during product preparation and administration; safety and effectiveness of co-administration with other intra-articular products have not been established.

Official Interaction Statements

There is a formally documented physical incompatibility between the active ingredient, Sodium Hyaluronate, and quaternary ammonium salts.
This incompatibility results in the localized precipitation of the product, which renders it unsuitable for use.
Regulatory instructions mandate that Synolis V-A must never come into contact with substances or equipment treated with quaternary ammonium salts (e.g., Benzalkonium Chloride).
The safety and effectiveness of co-administration with other products intended for intra-articular injection have not been formally established.

Connection to the Overall Interaction Profile

The regulatory interaction profile is defined exclusively by a critical local physical incompatibility with a class of disinfectants, necessitating an absolute prohibition of contact during administration. Official documents report no known systemic pharmacokinetic or pharmacodynamic interactions, consistent with the product’s local action as a medical device. The profile is further structured by the constraint that compatibility with other intra-articular injectables has not been established.

Mechanism of Action

The mechanism of action for Synolis V-A is primarily based on the rheological and physicochemical modulation of the synovial microenvironment. The formulation is composed of high-molecular-weight, non-animal-origin Hyaluronic Acid (HA) and Sorbitol.

HA functions by physically interacting with the existing synovial fluid components, restoring the viscoelasticity profile of the fluid space. The specific molecular weight and concentration contribute to an increase in the fluid's shear-thinning properties, which allows for mechanical energy absorption and load distribution during movement. Additionally, the exogenous HA polymer chain interacts with specific cell surface receptors, such as CD44 on synoviocytes and chondrocytes, potentially modulating their intracellular signaling pathways.

The co-formulated Sorbitol, a polyol, acts as a hydration stabilizer. Through its high water-binding capacity, Sorbitol minimizes the oxidative degradation and dissolution of the HA polymer, thereby preserving the structural integrity and high molecular weight of the injected viscoelastic material. This collective action results in the long-term physiological modulation of the joint space's biomechanical characteristics.

Dosage and Administration Information

How to Use Synolis V-A: Official Administration Guidelines

Synolis V-A is administered exclusively via Intra-Articular (IA) injection, which means it is delivered directly into the synovial cavity of the affected joint by a physician with expertise in this procedure. The use is strictly localized to the joint space; injection into the bloodstream (intravascular route) is prohibited. The medicine is available as a sterile, pre-filled syringe that is intended for single-use only and must not be reused or mixed with other solutions.

Official Dosing and Frequency Patterns

The following outlines two primary courses of administration depending on the severity and specific joint being managed:

Dosing Option	Strength and Volume	Frequency
Monoshot Course (Single Injection)	SYNOLIS VA 40/80 (2 mL) or SYNOLIS VA 80/160 (4 mL)	Administered as a one-time course.
Multi-Dose Course	SYNOLIS VA 40/80 (2 mL)	Administered as 3 injections, spaced one week apart in series.

Key Conditions for Administration

The procedural protocol defines essential conditions for safe and proper use. Before the injection, the viscoelastic solution must be allowed to reach room temperature. A key procedural requirement is that the physician must aspirate any significant joint effusion from the joint cavity before proceeding with the injection. Following the procedure, official instructions advise patients to avoid intense physical activity in the treated joint for a minimum of 48 hours. Retreatment may be performed to maintain functional benefit if the patient experiences a resumption of the original OA symptoms.

Recent Clinical Evidence

Research evidence / Overview of Studies for Synolis V-A

Evidence for use in Symptomatic Knee Osteoarthritis (OA)

Studies involving Synolis V-A have primarily focused on research participants with symptomatic mild to moderate osteoarthritis (OA) of the knee joint, typically Kellgren-Lawrence grades II or III. The research base contains randomized controlled trials (RCTs), frequently structured as non-inferiority comparisons, alongside post-hoc analyses derived from those trials. These studies were applied in research examining short-term symptom patterns, focusing on outcomes related to physical discomfort and daily functioning. The main outcomes monitored included measurements of pain severity and functional status using standardized patient-reported scales, as well as tracking the percentage of participants who met specific improvement criteria set by research organizations.

In these comparative trials, the research monitored how symptoms evolved when Synolis V-A was compared against a specific active comparator viscosupplement used in the study design. Studies reported patterns of measured pain and function changes tracked over the study period. Primary outcome assessments were typically reported at the 6-month (Day 168) time point.

Evidence for use in Symptomatic Hip Osteoarthritis (OA)

The research base for the hip joint contains fewer studies when compared to the research base for the knee. Studies in this area primarily consist of prospective case series and open-label trials, rather than large-scale RCTs. These studies were applied in research exploring short-term symptom changes in adults diagnosed with symptomatic hip OA. Research examined outcomes related to hip pain and recorded assessments of functional capacity. Studies reported patterns related to measured changes in pain and function, with follow-up generally conducted up to six months. Comparative evidence with established controls for the hip is lacking.

Research Gaps and Unanswered Questions

The available evidence, which includes non-inferiority RCTs for the knee, indicates the presence of several research limitations. There is limited information for long-term outcomes, as follow-up durations were primarily restricted to six months, and the certainty regarding sustained effects remains low. Furthermore, comparative evidence primarily assessed non-inferiority. The research base for the hip joint is less established, with a limited number of large-scale, comparative trials available. Research provides general context regarding group patterns and cannot determine whether an individual will experience similar measured changes.

Key Studies & References

Synolis VA Product Monograph (Used for study details and safety context)

Frequently Asked Questions (FAQ)

Common questions about Synolis V-A (FAQ)

Q: How quickly can I expect to feel relief after getting a Synolis V-A injection?

A: Clinical data from studies indicate that initial symptomatic improvement has been reported to be observed around Day 28 following the injection. It is important to know that individual patient responses and timelines for effect may vary.

Q: How long does the pain relief from a Synolis V-A injection typically last?

A: Clinical trials tracked and reported outcomes related to efficacy for Synolis V-A up to 6 months (168 days) post-injection. The studies generally reported that symptomatic response rates were maintained over this period.

Q: Is it normal to have some swelling or warmth in the joint after the injection?

A: Yes, temporary local reactions such as pain, swelling (oedema), and warmth at the injection site are classified as common adverse effects. These localized effects are typically expected to resolve spontaneously within a few days.

Q: What should I avoid doing right after receiving a Synolis V-A injection?

A: Official instructions advise patients to avoid intense physical activity in the treated joint for a minimum period of 48 hours following the injection procedure. This restriction is provided in the official instructions to support the safety and effectiveness of the localized treatment.

Q: Are there any long-term risks associated with repeated Synolis V-A use?

A: Official information notes that clinical data on the long-term outcomes beyond six months are limited. Retreatment is determined by a physician based on the patient’s experience, such as the resumption of the original osteoarthritis symptoms.

Q: Why do some people experience a temporary increase in pain right after the injection?

A: Injection-site pain is classified as a common, transient reaction. This temporary pain may be associated with the injection procedure itself or the transient localized effects of the viscoelastic solution within the joint space.

Q: Can a patient with diabetes safely get Synolis V-A injections?

A: The use in patients with an 'abnormal physiological condition,' such as diabetes, is not strictly prohibited. However, use requires a decision by the administering physician due to limited clinical data on tolerance and efficacy in these specific groups.

Q: Are there any specific activities or exercises that might reduce the effectiveness of Synolis V-A?

A: Official instructions advise patients to avoid intense physical activity for at least 48 hours after the procedure. Official instructions do not specifically identify other activities that may reduce long-term effectiveness.

Q: Do you need to rest the joint completely after getting a Synolis V-A shot?

A: The official instruction is to avoid intense physical activity in the joint for 48 hours. Complete rest or immobilization of the joint is not explicitly mandated in the regulatory documents.

Q: What is the typical recovery time after the injection site discomfort subsides?

A: According to the product information, common localized adverse reactions like pain, swelling, and warmth are generally transient. These effects are typically expected to resolve spontaneously within a few days.

Q: Is there an age limit for people receiving Synolis V-A treatment?

A: Yes, Synolis V-A is officially contraindicated in young people under the age of 18 years. This restriction is due to the limited clinical data on its use and tolerance in pediatric patients.

Q: Is Synolis V-A considered a biological or a synthetic product?

A: The active ingredient, Sodium Hyaluronate, is produced through a process called bio-fermentation, ensuring it is of non-animal origin. The product is regulated as a medical device for viscosupplementation.

Q: Are there any known effects of Synolis V-A on cartilage regeneration?

A: The primary purpose and indication for Synolis V-A are the reduction of pain and the improvement of joint mobility. Regulatory documents and research summaries generally focus on these symptomatic outcomes and do not provide information regarding any direct effects on cartilage regeneration.

Q: Does Synolis V-A improve joint function or just mask the pain?

A: Official product information states that Synolis V-A is indicated for both the reduction of pain and the improvement of joint mobility in affected joints. The physical restoration of the joint fluid's quality is intended to enhance joint lubrication and cushioning.

Q: Can Synolis V-A be used for people with early-stage arthritis?

A: The clinical research base has primarily focused on participants with symptomatic mild to moderate osteoarthritis (OA), specifically those with Kellgren-Lawrence grades II or III. Information regarding use in earlier, non-symptomatic stages is limited.

Q: Why is a specific injection technique required for Synolis V-A?

A: A physician with expertise must deliver the injection strictly into the joint space (Intra-Articular) for efficacy. The technique is also required to avoid the product coming into contact with certain disinfectants containing quaternary ammonium salts, which causes precipitation and renders the product unsuitable.

Q: Why does the packaging of Synolis V-A recommend refrigeration?

A: Official instructions mandate that the product must be stored at a temperature between 2°C and 25°C and protected from light. This specific range and protection are necessary to maintain the solution’s integrity and stability.

Q: Are there any non-arthritic conditions that Synolis V-A is used to treat?

A: The product is indicated solely for the management of pain and mobility issues in synovial joints affected by degenerative changes, such as those caused by Osteoarthritis (OA). Use is restricted to this official indication.

Q: Can Synolis V-A be administered by all types of healthcare professionals?

A: Official documents require that the injection be delivered by a physician who possesses the expertise necessary for performing intra-articular injection procedures.

How should Synolis V-A be stored and disposed of?

How to Store and Dispose of Synolis V-A

Official regulatory information requires Synolis V-A to be stored under specific environmental constraints to maintain product integrity. The product must be stored at a temperature between 2°C and 25°C (36°F and 77°F) and must be protected from light. It is explicitly required that the product must not be frozen or exposed to extreme cold.

Handling and Container Rules

Synolis V-A is supplied in a single-use pre-filled glass syringe. The contents must not be transferred into another container, mixed with other ingredients, or resterilized. The product must not be used if the packaging is damaged or if the labeled expiry date has lapsed.

Disposal

The used syringe and needle must be discarded in accordance with accepted medical practice and must comply with applicable national, local, and institutional requirements for pharmaceutical waste.

Synolis V-A